Compound Physician required WADA prohibited Part of Peptides

GHK-Cu

Copper peptide studied topically and systemically for skin repair and wound healing.

The story

GHK begins as an observation about blood plasma, not as a drug program. In 1973 Loren Pickart, then completing a biochemistry doctorate at the University of California, San Francisco under the hepatologist Marvin M. Thaler, reported that a factor present in human serum prolonged the survival of normal liver cells in culture while simultaneously stimulating the growth of hepatoma cells (Nature: New Biology 1973, PMID 4349963). His dissertation carried the finding in its title: A Tripeptide from Human Serum Which Enhances the Growth of Neoplastic Hepatocytes and the Survival of Normal Hepatocytes (UCSF, 1973, cited in Pickart et al. 2015). The dual finding — protective to normal cells, growth-stimulating to neoplastic ones — is worth registering at the outset, because it is the founding observation and it has never been resolved.

Identifying the sequence took four more years: in 1977 Schlesinger, Pickart and Thaler reported in Experientia that the growth-modulating serum tripeptide was glycyl-histidyl-lysine (DOI 10.1007/BF02002806). Copper arrived from chemistry rather than biology. Pickart and Thaler found in 1979 that recovering GHK from plasma depended on which transition metals were present (PMID 546910), and in 1980 a paper in Nature proposed that the tripeptide works by facilitating copper uptake into cells (DOI 10.1038/288715a0). The complex itself was pinned down in 1982, when Freedman, Pickart, Weinstein, Mims and Peisach published the solution structure of the GHK–copper(II) complex in Biochemistry (DOI 10.1021/bi00262a004). That is where GHK-Cu, as distinct from GHK, becomes a defined chemical entity — nine years after the first report.

Development ran through wound healing. In the late 1980s a connective-tissue group at Reims (Maquart, Gillery, Monboisse, Borel), collaborating with Pickart, showed GHK-Cu stimulated collagen synthesis in cultured fibroblasts (PMID 3169264) and, in 1993, connective-tissue accumulation in rat wounds (PMID 8227353). Commercially, Pickart co-founded ProCyte Corporation, took it public, and later founded Skin Biology with his wife Charlene (Seattle Times obituary). ProCyte's GHK-Cu wound gel, Iamin, was the product tested in the only clearly positive multicentre human trial in this literature — a randomized, evaluator-blinded, placebo-controlled study in diabetic neuropathic foot ulcers published in 1994 (DOI 10.1046/j.1524-475X.1994.20406.x). It never produced an approved drug; two years earlier a randomized evaluator-blinded trial in venous stasis ulcers had found a topical copper tripeptide complex cream no better than inert vehicle, with silver sulfadiazine outperforming both (DOI 10.1067/mva.1992.37086).

What did succeed was cosmetics. GHK-Cu entered the ingredient dictionary as Copper Tripeptide-1 and became a mainstream cosmeceutical active, supported by a set of company-run facial and eye-cream studies in women with photodamage conducted around 2002 — none of which was published as a peer-reviewed journal report (Pickart et al. 2015). That cosmetic record is the whole foundation of the compound's reputation, and it is a topical record.

The route into longevity culture is a documented pivot away from that. In 2012 an independent consortium (Boston University, Groningen, British Columbia, Pennsylvania) used the Broad Institute's Connectivity Map to search for compounds that reversed an emphysema gene-expression signature; GHK came out of the search, and the group validated it in cultured lung fibroblasts (DOI 10.1186/gm367). Pickart built a series of reviews on that result — culminating in the 2014 GHK and DNA: Resetting the Human Genome to Health (DOI 10.1155/2014/151479) and the 2015 claim that GHK "is capable of up- and downregulating at least 4,000 human genes" (DOI 10.1155/2015/648108) — and that sentence, more than any trial, is what carried GHK-Cu out of the skincare aisle and into peptide culture as a systemic anti-aging agent. Pickart died in 2023 (Seattle Times). He remains the single most frequent author in the GHK literature: 16 of the ~220 PubMed-indexed records on GHK / GHK-Cu / copper tripeptide carry him as an author (PubMed author query, retrieved 2026-08-28), and he authored essentially all of the widely-cited review syntheses from which the popular claims are drawn — though, unlike the BPC-157 literature, this one also contains substantial work from groups with no connection to him.

  1. 1973 Pickart and Thaler report a human-serum factor that prolongs normal liver-cell survival and stimulates hepatoma growth; a synthetic tripeptide reproduces it
  2. 1977 Sequence identified as glycyl-histidyl-lysine (Schlesinger, Pickart, Thaler)
  3. 1980 Nature: GHK proposed to act by facilitating copper uptake into cells — the origin of "GHK-Cu"
  4. 1982 Solution structure of the GHK–Cu(II) complex published in Biochemistry
  5. 1992 Randomized evaluator-blinded venous-stasis-ulcer trial: a topical copper tripeptide complex cream no better than vehicle
  6. 1994 Multicentre randomized placebo-controlled trial: ProCyte's Iamin (GHK-Cu) gel accelerates closure of diabetic neuropathic foot ulcers
  7. 2006 Randomized trial of GHK-Cu skincare after CO₂ laser resurfacing: no objective benefit on erythema or wrinkles; one subjective questionnaire item favoured GHK-Cu
  8. 2012 Connectivity Map screen by a four-university consortium identifies GHK as reversing an emphysema gene signature; validated in cultured lung fibroblasts
  9. 2014–2015 Pickart's "resetting the human genome" reviews publish the "at least 4,000 human genes" formulation
  10. 2026-07 GHK-Cu is not among the substances considered at FDA's Pharmacy Compounding Advisory Committee meeting; its 503A bulks nomination had been withdrawn
  11. 2026-08 No modern controlled trial of GHK-Cu is known to be underway. A registry record asserting one was withdrawn from this dossier on 2026-08-29 as unverifiable; the milestone table's last genuine entry remains 2012 for mechanism and 1994–2006 for human trials

What it does

A copper peptide with the most human data of any research peptide — but nearly all of it is topical/dermatological. The systemic longevity claims extrapolate well beyond that evidence.

Glycyl-histidyl-lysine bound to copper, a naturally occurring peptide hypothesized to support collagen synthesis, wound healing, and antioxidant activity through copper-dependent enzymatic pathways.

  • skin repair
  • wound healing
  • collagen synthesis

What the evidence shows

The route asymmetry is the finding. Real controlled human data on GHK-Cu exists — which separates it from most of this batch — but every scrap of it is topical, onto skin or onto an open wound, and it is smaller and more mixed than the reputation: a 2026 PRISMA systematic review found 20 eligible studies, only 2 of them RCTs, and of the three peer-reviewed randomized trials one was positive (diabetic neuropathic ulcers, the sponsor's own product, from a company the compound's discoverer co-founded) and two were negative. The controlled cosmetic studies that produce the familiar wrinkle-depth, skin-density and photodamage results were never peer-reviewed at all: two AAD conference proceedings, a Marcel Dekker book chapter and one report in a non-indexed journal, none retrievable in primary form, all four reaching this dossier only secondhand through two reviews — and not one of the four ever published the concentration it tested, so no marketed serum can be tied to any studied exposure. For the injectable and systemic use that actually circulates in peptide culture there is no human data of any kind — no trial, no pharmacokinetics, and no measurement of copper status in any person by any route, and no modern controlled trial is known to be underway; the single exception anywhere in the human record is one uncontrolled intradermal scalp injection of a six-ingredient blend from which GHK-Cu's contribution cannot be isolated. The literature's single biggest limitation is that it is dominated by one author who was also the compound's commercial developer: Loren Pickart carries 16 of roughly 220 indexed records, wrote essentially every review synthesis the popular claims are drawn from, and co-founded the company whose product was the intervention in the one clearly positive randomized trial — and the "resets at least 4,000 genes" sentence that carried GHK-Cu out of skincare and into injectable culture traces back through a 50% change cutoff the authors chose themselves after seeing their own results, applied to a database of cultured cell lines, and never measured in a person.

Overall evidence strength: Low certainty

  • Mulder GD et al. (1994) — diabetic neuropathic foot ulcers (1994) Randomized controlled trial

    Applied onto a freshly debrided diabetic foot ulcer, the copper-peptide gel closed the wound about three times faster than vehicle (median 98.5% area closure vs 60.8%) — a real result about putting a copper peptide onto an open wound, which says nothing about intact skin or systemic use.

    Source PMID 17147644

  • Bishop JB et al. (1992) — venous stasis ulcers (1992) Randomized controlled trial

    The copper peptide cream did no better than plain vehicle and silver sulfadiazine beat both — the same molecule that worked on debrided diabetic ulcers did nothing measurable on venous ulcers, which cautions against "GHK-Cu heals wounds" as a general property.

    Source PMID 1495150

  • Miller TR et al. (2006) — CO₂ laser-resurfaced facial skin (2006) Randomized controlled trial

    Everyone improved and adding GHK-Cu made no measurable difference to redness, wrinkles or skin quality; the only separation was how patients rated their own skin (p=0.04).

    Source PMID 16847171

  • The cosmetic photodamage studies (1998–2005)

    At face value these are placebo-controlled 12-week studies in exactly the population that buys the product, reporting a consistent direction of effect. But none went through journal peer review, none has a public protocol or dataset, the investigators and sponsors were cosmetic-industry parties, and the results reach us only through a review written by the compound's discoverer and commercial developer — ordinary evidence by cosmetic-science standards, not confirmatory by clinical-trial standards.

    Source

  • Badenhorst T, Svirskis D, Merrilees M (2016) — facial wrinkle parameters (2016)

    The one modern-looking controlled cosmetic trial — published in Journal of Aging Science, an OMICS International title (DOI prefix 10.4172); a US federal court entered a $50.1 million judgment against OMICS in an FTC action over deceptive claims about its journals' peer review (FTC, 2019). Reported because it is widely cited; the venue's peer review is not treated as meaningful. The report is also no longer retrievable: on 2026-08-29 the DOI still resolved, but through two successor domains to a PDF host that did not respond, so the primary text could not be read even to check what this dossier says about it.

    Source

  • Campbell JD et al. (2012) — the gene-expression study everything traces back to (2012) Preclinical / mechanistic

    A database search nominated GHK as a candidate for reversing an emphysema gene signature, and adding GHK to COPD fibroblasts in a dish restored their ability to contract collagen gel — hypothesis-generating in cells, not a treatment result in people, and no human COPD trial has followed in fourteen years.

    Source PMID 22937864

What studies used — not a recommendation.

  • 20 volunteers, normal thigh skin · Topical cream containing a copper-binding peptide (GHK-Cu) applied to one thigh; melatonin, vitamin C or retinoic acid creams as comparators on other sites; skin biopsies at baseline and end · 1 month
  • 71 women (facial photoaging); 41 women (periocular photodamage, vs placebo and a vitamin K cream); 67 women aged 50–59 (twice daily, with biopsy histology) · GHK-Cu cosmetic cream applied to the study area, as described by each study (eye-cream study also compared against placebo and a vitamin K cream) · 12 weeks each
  • 13 adults after circumoral CO₂ laser resurfacing · Post-treatment skincare regimen with or without GHK-Cu products · 12 weeks

Common misconceptions

“GHK-Cu is one of the best-evidenced peptides there is — so injecting it works.”

The premise is half true and the conclusion does not follow. GHK-Cu genuinely has a human evidence base most of this batch lacks — but every human study of GHK-Cu has been topical, onto skin or an open wound, with the single exception of an intradermal scalp injection of a six-ingredient blend. The claim also inverts the two results it rests on. GHK-Cu's clearest human benefit came on debrided diabetic foot ulcers, where the mechanism is a copper peptide in direct contact with granulating tissue (DOI 10.1046/j.1524-475X.1994.20406.x). Where it was tested on skin that was damaged but not open — CO₂ laser resurfacing — it produced no measurable objective benefit (DOI 10.1001/archfaci.8.4.252). Honest answer: "Topical GHK-Cu has evidence" and "injected GHK-Cu has evidence" are different sentences, and only the first is true. The systemic case is a mechanistic and gene-expression argument, and the dose figures attached to it are an author's scaling of rodent experiments, not a trial result.

“GHK-Cu delivers copper, so it will load you with copper and wreck your copper-to-zinc ratio.”

Almost nothing, in either direction. Copper is roughly 16% of GHK-Cu's mass, so the compound does carry copper. But no human study of GHK-Cu by any route has measured serum copper, ceruloplasmin or zinc — a PubMed search combining GHK-Cu or copper tripeptide with ceruloplasmin, serum copper or copper status returns three records, none a human clinical study (retrieved 2026-08-28). For context, copper's adult Tolerable Upper Intake Level is 10,000 µg/day, set on liver damage, and the documented zinc–copper interaction runs the other way — high zinc impairs copper absorption, not the reverse (NIH ODS). The mechanistic literature also cuts against the "free copper" worry: GHK binds copper and reduces its redox activity, and in vitro prevented copper- and zinc-induced protein aggregation and CNS cell death (DOI 10.1093/mtomcs/mfae019). Honest answer: Open, and structurally so. Nobody has measured copper status in a person given GHK-Cu, so the reassurance and the alarm are equally unevidenced. The reason it matters more for injection than for cream is that a cosmetic delivers copper to the stratum corneum, while an injection bypasses every absorptive control the body has for copper.

“GHK-Cu resets 4,000 genes to a healthier state.”

The sentence is a three-step chain, and the load-bearing step is a threshold the authors chose after seeing their own results. Step 1. Pickart, Vasquez-Soltero and Margolina wrote in 2015 that GHK "is capable of up- and downregulating at least 4,000 human genes, essentially resetting DNA to a healthier state" (DOI 10.1155/2015/648108). Step 2 — the crux. The 2018 companion gives the underlying figure: "The number of human genes stimulated or suppressed by GHK with a change greater than or equal to 50% is 31.2%" (DOI 10.3390/ijms19071987). That 50% cutoff was not a pre-specified statistical threshold. It was chosen post hoc by the authors themselves, on their own stated reasoning that it "gave the best correlation with our biological data." Move the cutoff and the gene count moves with it; "4,000" is a function of where the authors drew the line after looking. Steps 1 and 2 are the same three authors, so the 2018 paper does not corroborate the 2015 sentence — it is the same entity explaining itself. Step 3. The underlying data is the Broad Institute's Connectivity Map, a reference database of expression signatures produced by exposing cultured human cell lines to compounds and reading microarrays (Lamb et al., Science 2006). "4,000 genes" counts probes that moved by at least half in that assay. It measures how broadly a compound perturbs transcription in a dish. It carries no directionality toward health. And the chain has never been checked. The per-gene data behind the 31.2% figure has never been independently re-analysed or published as a standalone dataset, and nothing in the chain — not one step — was measured in a person. This is the claim that moved GHK-Cu out of the skincare aisle and into injectable peptide culture. Honest answer: The number is real and the interpretation is not. Broad transcriptional perturbation in cultured cells would describe many compounds nobody calls rejuvenating; "resetting DNA to a healthier state" is editorial language layered on top of it by the compound's discoverer and commercial developer.

“It's a peptide your body already makes and loses with age, so replacing it is just restoration.”

GHK is genuinely endogenous — unlike BPC-157, this is not disputed — and plasma levels are reported to decline with age (DOI 10.1155/2015/648108). But the founding observation was that the same factor prolonged survival of normal liver cells and stimulated growth of hepatoma cells (PMID 4349963), and GHK-Cu's documented actions include angiogenesis and fibroblast proliferation. "Endogenous" and "declines with age" describe where a molecule comes from, not what happens when you raise it above physiological levels by a route the body never uses. No study in any species has evaluated whether systemic GHK-Cu promotes or inhibits tumour growth in a living animal with cancer.

“The cosmetic evidence settles that topical copper peptides work.”

Better than most cosmeceutical evidence, weaker than it is usually presented as being. The four studies generating the wrinkle-depth, skin-density and photodamage claims were published as AAD conference proceedings, a book chapter, and one non-indexed journal report — not T1 under this file's source tiers, and not peer-reviewed at all. And not one of the four ever published the concentration of GHK-Cu it tested, which limits what any cosmetic claim built on them can mean: even taken at face value, the results attach to four unretrievable products of unstated strength, so no serum a reader can buy is tied to any studied exposure. "Copper peptides work" and "this copper peptide product works" are different sentences, and this literature cannot reach the second. An independent 2025 pharmaceutics review concluded there is "a surprising absence of clinical studies" using GHK-Cu and argued from physicochemistry that stratum-corneum permeation is a real obstacle (DOI 10.34172/bi.30071). Two academics writing in The Conversation in January 2026 (Ahmed Elbediwy, Nadine Wehida) take the opposite view, calling copper peptides "backed by science," while noting documented skin irritation and mild allergic reactions in a minority of users and instability when copper peptides are combined with vitamin A and vitamin C formulations (The Conversation, 2026-01-23). ⚠️ Unresolved; both positions are in the published record. ---

Who it's for, who should skip

Topical cosmetic use is widely available over the counter. Systemic/injectable longevity use is off-label and gray_zone — on the announced ~Feb 2027 PCAC agenda, with supplier-quality and copper-accumulation concerns; not established beyond its topical dermatological effects.

Running it

No dosing protocol is published for this compound — there is no lawful supervised channel for the use this guide covers. What follows is monitoring, expectations, and safety framing only.

What to expect

  • Onset — wounds (days) — On debrided diabetic neuropathic ulcers, closure proceeded roughly three times faster than with vehicle across the treatment course; the paper notes the advantage required treatment to begin immediately after initial debridement (Confidence: T1, trial-documented — DOI 10.1046/j.1524-475X.1994.20406.x)
  • Onset — skin (weeks) — Cosmetic studies assessed at 8 and 12 weeks. Procollagen change was detectable on biopsy at 1 month in the thigh study; the facial and eye studies reported their endpoints at 12 weeks (Confidence: Not T1 — trial-reported in non-peer-reviewed venues (conference proceedings and a book chapter), reaching this dossier secondhand (summarized in DOI 10.1155/2015/648108))
  • Post-cessation — Not studied in humans by any route. No study has followed participants after stopping (Confidence: No data)
  • Long-term — No human study of any duration beyond 12 weeks. The CIR's cosmetic safety conclusion rests on present practices of use, not on longitudinal outcome data (CIR) (Confidence: No data)
  • Systemic / injected use — any phase — Nothing. No onset, plateau, duration or cessation data exists for any systemic route in any human (Confidence: No data)
  • Next real answer expected — No credible pending readout identified. No modern controlled trial of GHK-Cu is known to be underway. A registry record asserting one was withdrawn from this dossier on 2026-08-29 as unverifiable, and nothing else stands behind this row. The most recent peer-reviewed randomized human trial of GHK-Cu was published in 2006 (Confidence: Absence finding)

Response signs

Likely working

  • Faster closure and lower infection rate of a debrided diabetic neuropathic foot ulcer under standardized wound care — T1, trial-documented (randomized, evaluator-blinded, vehicle-controlled) · DOI 10.1046/j.1524-475X.1994.20406.x Trial-documented
  • Visible improvement in fine lines, laxity and skin firmness over 8–12 weeks of topical use — Not T1 — trial-reported, non-peer-reviewed venue, reaching us secondhand through the discoverer's own review; not reproduced on objective measures in the T1 randomized trial · DOI 10.1155/2015/648108; DOI 10.1001/archfaci.8.4.252 Trial-reported
  • Feeling that skin looks better after a resurfacing procedure — T1, trial-documented but subjective only — the questionnaire item separated groups; the instruments did not · DOI 10.1001/archfaci.8.4.252 Trial-documented
  • Any systemic effect — energy, recovery, sleep, "anti-aging" — Anecdotal, low confidence. No human systemic exposure has ever been studied Anecdotal

Adverse — seek review

  • Skin irritation, redness, stinging, or a mild allergic reaction at the application site — Reported for cosmetic topical use in a minority of users — independent expert commentary, qualitative, not a clinical figure · The Conversation, 2026-01-23
  • Any systemic reaction — fever, rash, malaise — after an injected product — Inference, not documented. Flagged because tested gray-market peptide purity has run as low as 5%, so most of a vial's content may not be the labelled compound · ECRI/ISMP, 2026 Inference

Common / neutral

  • No perceptible sensation of any kind — Consistent with the record. GHK-Cu has no acute felt effect in any documented human exposure · .

Getting it right

  • Monitoring: There is no efficacy biomarker. Nothing validated predicts or confirms response. Any monitoring plan is safety monitoring or photographic documentation, not effectiveness monitoring. mitigate side effect
  • Monitoring: Copper status is the plausible thing to have measured and the thing nobody has measured. Its relevance is specific to routes that bypass intestinal copper regulation, not to cosmetics. mitigate side effect
  • General safety: Route determines almost the whole risk picture. For cosmetic topical use the CIR panel concluded the ingredient is safe in present practices of use and concentration (CIR); documented issues are local irritation, mild allergic reaction in a minority, and instability combined with vitamin A and C products (The Conversation). For injected use there is no human safety dataset of any size (PMID 41966639). mitigate side effect
  • General safety: Product identity dominates for anything injectable. ECRI and ISMP reported gray-market peptide purity of 5–75% with arsenic and lead above toxicity thresholds; a seller-supplied certificate of analysis is not independent verification (an expert-body publication — alongside T1 for product quality, never for a clinical figure — and the single source for this whole picture — ECRI/ISMP, 2026). mitigate side effect
  • General safety: Blended products defeat attribution. The only injected human GHK-Cu exposure on record was a six-ingredient blend, and nothing in its result can be assigned to GHK-Cu (PMID 29482481). An adverse event in a blend cannot be attributed either. mitigate side effect
  • The physician conversation: Which route is actually under discussion — a cosmetic applied to skin, or something injected? (Fifty years of evidence for the first; none for the second.) mitigate side effect
  • The physician conversation: What is the goal, and is there an approved option with randomized evidence for it? (Retinoids for photoaging; minoxidil or finasteride for hair loss; standard wound care for ulcers.) mitigate side effect
  • The physician conversation: Any personal or family history of a copper-handling disorder, or of liver disease? mitigate side effect
  • The physician conversation: What is the personal and family cancer history? (— an open question, not a documented signal.) mitigate side effect
  • The physician conversation: What would count as it working, by when, and what is the plan if that date passes? mitigate side effect
  • The physician conversation: Any competitive-sport or military testing obligation? (— genuinely unsettled for this compound.) mitigate side effect

Safety

  • topical use generally well-tolerated; systemic use carries supplier-quality and uncharacterized copper-accumulation concerns

Stacking & alternatives

  • Complements KPV — Both short endogenous-derived peptides pitched for inflammation and repair; KPV went to the July 2026 PCAC vote and GHK-Cu did not (FDA PCAC)

Access & cost

The topical cosmetic form is available over the counter — look for GHK-Cu cosmetic serums. The injectable or systemic form has no lawful channel — see the status note above.

GHK-Cu is different from the rest of this batch: a lawful channel exists. Copper Tripeptide-1 is a lawfully marketed cosmetic ingredient, reviewed and found safe as used by the CIR Expert Panel (CIR 2014), and copper-peptide serums are sold at ordinary retail. Trade reporting in April 2026 put newly launched peptide skincare products in a band from roughly $50 to $160, with a copper tripeptide (GHK-Cu) serum at the top of that band (Glossy, 2026-04-20). That is the published cost context, and it is a cosmetic one. There is no lawful channel to price injectable GHK-Cu. It is not FDA-approved and its 503A bulks nomination was withdrawn, so there is no legitimate compounded or prescribed price to report (FDA). A gray market for injectable peptides including GHK-Cu nonetheless exists and has been documented in the peer-reviewed clinical literature as a "parallel 'gray market' of unapproved compounds… operating largely outside of regulatory oversight" (PMID 41966639). we found no journalist-reported specific price figure for gray-market injectable GHK-Cu. If one is located later, it belongs in a marked internal subsection, not in the published cosmetic pricing above. ---

Questions

Should I use copper peptides topically or inject them?
The most-searched question about GHK-Cu, and the evidence answers it lopsidedly: every human study of GHK-Cu has been topical. Injectable GHK-Cu has no human trial, no published pharmacokinetics and no safety data; the case for it is mechanistic plus a gene-expression argument, and the circulating dose figures are an author's scaling of rodent experiments (DOI 10.1155/2015/648108). Sellers present the comparison as a real choice between two evidenced options (example, cited as evidence of what is claimed). It is not: one arm has fifty years of topical data and the other has none. But do not read the topical arm as more actionable than it is. No cosmetic GHK-Cu study ever published a concentration — so even on the topical side, no serum you can buy can be tied to any studied exposure. The choice the evidence actually supports is between a route with real but unquantified topical data and a route with no human data at all; it is not a choice between two products of known strength.
Does GHK-Cu actually work?
For open wounds treated topically, one randomized placebo-controlled trial says yes for debrided diabetic neuropathic ulcers (DOI 10.1046/j.1524-475X.1994.20406.x) and another says no for venous stasis ulcers (DOI 10.1067/mva.1992.37086). For cosmetic skin appearance, four company-run 8–12 week studies report benefit but none was peer-reviewed, and the one randomized post-laser trial found no objective benefit (DOI 10.1001/archfaci.8.4.252). The 2026 systematic review counted 20 studies, 2 of them RCTs (DOI 10.1093/asj/sjag169).
How long until copper peptides work?
The cosmetic studies read their endpoints at 8 or 12 weeks, with one biopsy study at 1 month. Nothing documents a shorter timeframe, and nothing documents what happens after 12 weeks, because no study ran longer.
Does GHK-Cu cause copper toxicity?
Unknown, because it has never been measured: no human study of GHK-Cu by any route has reported serum copper, ceruloplasmin or zinc. Copper's adult upper intake level is 10,000 µg/day, set on liver damage (NIH ODS); in cell culture GHK reduces copper's redox activity rather than increasing it (DOI 10.1093/mtomcs/mfae019). Both the reassurance and the alarm are unevidenced, and the concern is structurally larger for injection than for cream.
What are the side effects?
For cosmetic topical use the CIR Expert Panel concluded Copper Tripeptide-1 is safe as currently used (CIR 2014); reported reactions are skin irritation and mild allergic reactions in a minority, plus formulation instability with vitamin A and vitamin C products (The Conversation). For injected use there is no human safety dataset at all (PMID 41966639).
Will it show up on a drug test?
GHK-Cu is not named on the WADA Prohibited List and no validated anti-doping detection method has been published — which is not the same as being cleared. The claim that it is banned anyway under S0 comes from a single commercial testing company's blog, not from any anti-doping body. See.
Is what I'd buy actually GHK-Cu?
Cosmetics containing Copper Tripeptide-1 are a regulated lawful category. Injectable "research" vials are not: ECRI and ISMP reported gray-market peptide purity ranging from 5% to 75% with arsenic and lead above toxicity thresholds (ECRI/ISMP, 2026 — an expert-body publication, which sits alongside T1 for product-quality and market-conduct facts and never for a clinical figure; and it is a single joint patient-safety release, the sole source for every product-quality and heavy-metals figure in this dossier, cited five times and not corroborated anywhere else in this file). Those figures describe the gray peptide market generally; the source does not attribute them to GHK-Cu, and neither do we. ---

Last reviewed 27 August 2026. Regulatory status verified 27 August 2026.